Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

Abstract

Plasma postoperative ctDNA detected MRD and identified patients at high risk of relapse in localized CC. Mutation tracking with more than one variant in serial plasma samples improved our accuracy in predicting MRD.